Literature DB >> 18645594

The role of stress proteins in prostate cancer.

Alan So1, Boris Hadaschik, Richard Sowery, Martin Gleave.   

Abstract

The development of therapeutic resistance, after hormone or chemotherapy for example, is the underlying basis for most cancer deaths. Exposure to anticancer therapies induces expression of many stress related proteins, including small heat shock proteins (HSPs). HSPs interact with various client proteins to assist in their folding and enhance the cellular recovery from stress, thus restoring protein homeostasis and promoting cell survival. The vents of cell stress and cell death are linked, as the induction of molecular chaperones appears to function at key regulatory points in the control of apoptosis. On the basis of these observations and on the role of molecular chaperones in the regulation of steroid receptors, kinases, caspases, and other protein remodelling events involved in chromosome replication and changes in cell structure, it is not surprising that molecular chaperones have been implicated in the control of cell growth and in resistance to various anticancer treatments that induce apoptosis. Recently, several molecular chaperones such as Clusterin and HSP27 have been reported to be involved in development and progression of hormone-refractory prostate cancer. In this review, we address some of the molecular and cellular events initiated by treatment induced stress, and discuss the potential role of chaperone proteins as targets for prostate cancer treatment.

Entities:  

Keywords:  Clusterin; OGX-011; Prostate cancer; antisense oligonucleotide; apoptosis; chemotherapy; heat shock protein

Year:  2007        PMID: 18645594      PMCID: PMC2430682          DOI: 10.2174/138920207781386951

Source DB:  PubMed          Journal:  Curr Genomics        ISSN: 1389-2029            Impact factor:   2.236


  124 in total

1.  The cochaperone Bag-1L enhances androgen receptor action via interaction with the NH2-terminal region of the receptor.

Authors:  Liubov Shatkina; Sigrun Mink; Hermann Rogatsch; Helmut Klocker; Gernot Langer; Andrea Nestl; Andrew C B Cato
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

2.  Synthesis and functional analyses of nuclear clusterin, a cell death protein.

Authors:  Konstantin S Leskov; Dmitry Y Klokov; Jing Li; Timothy J Kinsella; David A Boothman
Journal:  J Biol Chem       Date:  2003-01-24       Impact factor: 5.157

3.  Principles of chaperone-assisted protein folding: differences between in vitro and in vivo mechanisms.

Authors:  J Frydman; F U Hartl
Journal:  Science       Date:  1996-06-07       Impact factor: 47.728

4.  Discovery of the heat shock response.

Authors:  F Ritossa
Journal:  Cell Stress Chaperones       Date:  1996-06       Impact factor: 3.667

5.  A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer.

Authors:  Kim N Chi; Elizabeth Eisenhauer; Ladan Fazli; Edward C Jones; S Larry Goldenberg; Jean Powers; Dongsheng Tu; Martin E Gleave
Journal:  J Natl Cancer Inst       Date:  2005-09-07       Impact factor: 13.506

6.  Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2.

Authors:  Andrea D Basso; David B Solit; Pamela N Munster; Neal Rosen
Journal:  Oncogene       Date:  2002-02-14       Impact factor: 9.867

7.  Plasma levels of heat shock protein 70 in patients with prostate cancer: a potential biomarker for prostate cancer.

Authors:  Miyako Abe; Judith B Manola; William K Oh; Diane L Parslow; Daniel J George; Carolyn L Austin; Philip W Kantoff
Journal:  Clin Prostate Cancer       Date:  2004-06

8.  Heat shock protein expression and drug resistance in breast cancer patients treated with induction chemotherapy.

Authors:  L M Vargas-Roig; F E Gago; O Tello; J C Aznar; D R Ciocca
Journal:  Int J Cancer       Date:  1998-10-23       Impact factor: 7.396

9.  Molecular determinants of resistance to antiandrogen therapy.

Authors:  Charlie D Chen; Derek S Welsbie; Chris Tran; Sung Hee Baek; Randy Chen; Robert Vessella; Michael G Rosenfeld; Charles L Sawyers
Journal:  Nat Med       Date:  2003-12-21       Impact factor: 53.440

10.  Enhanced activity of an antisense oligonucleotide targeting murine protein kinase C-alpha by the incorporation of 2'-O-propyl modifications.

Authors:  R A McKay; L L Cummins; M J Graham; E A Lesnik; S R Owens; M Winniman; N M Dean
Journal:  Nucleic Acids Res       Date:  1996-02-01       Impact factor: 16.971

View more
  14 in total

1.  Differential expression of peroxiredoxins in prostate cancer: consistent upregulation of PRDX3 and PRDX4.

Authors:  Anamika Basu; Hiya Banerjee; Heather Rojas; Shannalee R Martinez; Sourav Roy; Zhenyu Jia; Michael B Lilly; Marino De León; Carlos A Casiano
Journal:  Prostate       Date:  2010-10-28       Impact factor: 4.104

2.  Peptides modulating conformational changes in secreted chaperones: from in silico design to preclinical proof of concept.

Authors:  Yossef Kliger; Ofer Levy; Anat Oren; Haim Ashkenazy; Zohar Tiran; Amit Novik; Avi Rosenberg; Anat Amir; Assaf Wool; Amir Toporik; Ehud Schreiber; Dani Eshel; Zurit Levine; Yossi Cohen; Claudia Nold-Petry; Charles A Dinarello; Itamar Borukhov
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-05       Impact factor: 11.205

3.  Differential expression of Annexin 2, SPINK1, and Hsp60 predict progression of prostate cancer through bifurcated WHO Gleason score categories in African American men.

Authors:  Desta A Beyene; Tammey J Naab; Norma F Kanarek; Victor Apprey; Ashwini Esnakula; Farahan A Khan; Marc R Blackman; Collis A Brown; Tamaro S Hudson
Journal:  Prostate       Date:  2018-04-22       Impact factor: 4.104

4.  Pathway specific gene expression profiling reveals oxidative stress genes potentially regulated by transcription co-activator LEDGF/p75 in prostate cancer cells.

Authors:  Anamika Basu; Awa Drame; Ruben Muñoz; Rik Gijsbers; Zeger Debyser; Marino De Leon; Carlos A Casiano
Journal:  Prostate       Date:  2011-07-27       Impact factor: 4.104

Review 5.  Heat shock protein 27 phosphorylation: kinases, phosphatases, functions and pathology.

Authors:  Sergiy Kostenko; Ugo Moens
Journal:  Cell Mol Life Sci       Date:  2009-07-11       Impact factor: 9.261

6.  Update on options for treatment of metastatic castration-resistant prostate cancer.

Authors:  Prakash Vishnu; Winston W Tan
Journal:  Onco Targets Ther       Date:  2010-06-24       Impact factor: 4.147

7.  Cabazitaxel inhibits prostate cancer cell growth by inhibition of androgen receptor and heat shock protein expression.

Authors:  Anja-Martina Rottach; Hannes Ahrend; Benedikt Martin; Reinhard Walther; Uwe Zimmermann; Martin Burchardt; Matthias B Stope
Journal:  World J Urol       Date:  2019-01-02       Impact factor: 4.226

Review 8.  Unfolded protein response in cancer: the physician's perspective.

Authors:  Xuemei Li; Kezhong Zhang; Zihai Li
Journal:  J Hematol Oncol       Date:  2011-02-23       Impact factor: 17.388

9.  Docetaxel-induced prostate cancer cell death involves concomitant activation of caspase and lysosomal pathways and is attenuated by LEDGF/p75.

Authors:  Melanie Mediavilla-Varela; Fabio J Pacheco; Frankis Almaguel; Jossymar Perez; Eva Sahakian; Tracy R Daniels; Lai Sum Leoh; Amelia Padilla; Nathan R Wall; Michael B Lilly; Marino De Leon; Carlos A Casiano
Journal:  Mol Cancer       Date:  2009-08-28       Impact factor: 27.401

10.  Clusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma model.

Authors:  Y Kususda; H Miyake; M E Gleave; M Fujisawa
Journal:  Br J Cancer       Date:  2012-05-15       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.